NASDAQ:ACTU
Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. reported net income of −$22.2M in fiscal 2025. The diluted share count rose 151.1%.Summary generated from Actuate Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−553.7%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+151.1%
Financials
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | n/a | n/a | n/a |
| Operating income | −25 | −25 | −22 |
| Net income | −25 | −27 | −22 |
| Free cash flow | n/a | n/a | n/a |
Recent filings
- S-1Registration statement
Oct 6, 2026 - 4Insider transaction report
Aug 14, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KNotice of delisting or listing-rule failure
Jul 17, 2026 - 8-KResults of a shareholder vote
May 22, 2026 - 4Insider transaction report
May 22, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 14, 2026 - 8-KRegulation FD disclosure
May 11, 2026